Rexahn Pharmaceuticals has completed patient enrollment in its Phase II clinical trial designed to investigate the ability of Archexinin to treat metastatic pancreatic cancer.

Archexin, an Akt protein kinase inhibitor, inhibits cancer cell survival and proliferation, angiogenesis and drug resistance.

Phase I clinical trial data has shown that Archexin has a human safety profile, with fatigue being the only side effect.

The two-stage, single arm, open label study in combination with gemcitabine enrolled approximately 35 patients to evaluate the overall survival rate of the patients treated with the drug candidate.

Rexahn president and chief operating officer Rick Soni said they expect to report preliminary results in the first half of 2012.

Archexin has obtained FDA orphan drug designation to treat renal cell carcinoma, glioblastoma, pancreatic, stomach and ovarian cancers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData